Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Neurocrine Biosciences Inc., 3 years.
Neurocrine Biosciences Inc.
Director
Arcus Biosciences Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2025 | Gilead Sciences Inc. | Open-market sale | −3,000 | $110.17 | $330,510 |
| Jun 10, 2025 | Gilead Sciences Inc. | Option exercise | +3,843 | — | — |
| Jun 10, 2025 | Gilead Sciences Inc. | Shares withheld for tax | −1,827 | $110.09 | $201,134 |
| Mar 10, 2025 | Gilead Sciences Inc. | Option exercise | +8,080 | — | — |
| Mar 10, 2025 | Gilead Sciences Inc. | Shares withheld for tax | −3,907 | $117.21 | $457,939 |
| Feb 4, 2025 | Gilead Sciences Inc. | Grant or award | +19,793 | — | — |
| Feb 4, 2025 | Gilead Sciences Inc. | Grant or award | +70,712 | — | — |
| Feb 4, 2025 | Gilead Sciences Inc. | Shares withheld for tax | −45,666 | $97.99 | $4,474,811 |
| Dec 10, 2024 | Gilead Sciences Inc. | Option exercise | +3,752 | — | — |
| Dec 10, 2024 | Gilead Sciences Inc. | Shares withheld for tax | −1,739 | $92.34 | $160,579 |
| Nov 6, 2024 | Gilead Sciences Inc. | Open-market sale | −5,000 | $91.28 | $456,400 |
| Sep 12, 2024 | Gilead Sciences Inc. | Open-market sale | −15,925 | $84.23 | $1,341,363 |
| Sep 12, 2024 | Gilead Sciences Inc. | Open-market sale | −13,432 | $83.25 | $1,118,214 |
| Sep 10, 2024 | Gilead Sciences Inc. | Option exercise | +3,752 | — | — |
| Sep 10, 2024 | Gilead Sciences Inc. | Shares withheld for tax | −1,734 | $81.44 | $141,217 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.